Trends in the use of evidence-based therapies early in the course of acute myocardial infarction and its influence on short term patient outcomes

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 171-178

  Al Jarallah, Mohammad ^a   Al Mallah, Mouaz H ^b   Zubaid, Mohammad ^c   Alsheikh Ali, Alawi A ^d   Rashed, Wafa ^e   Ridha, Mustafa ^f   Alenizi, Fahad ^g   Bulbanat, Bassam ^a   Akbar, Mousa ^h   Al Hamdan, Rashed ⁱ   Zubair, Shahid ^j  

^a Al Amiri Hospital   (United Kingdom)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c KUWAIT UNIVERSITY   (Kuwait)

^d SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^e Mubarak Alkabeer Hospital   (Kuwait)

^f AL ADAN HOSPITAL   (Kuwait)

^g Al Farwaniya Hospital   (Kuwait)

^h Division of Cardiology   (Kuwait)

ⁱ Aljahra Hospital   (Kuwait)

^j KUWAIT OIL COMPANY   (Kuwait)

more..

Author keywords

Acute coronary syndrome; Evidence based therapies; Outcomes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HOSPITAL CARE; HUMAN; KUWAIT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; TREND STUDY;

EID: 80053514750     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010171     Document Type: Article

References (40)

1. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745-9.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: E1-E211.
3. Anderson JF, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/ Non-ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2007; 50: 652-726.
4. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lop Sendon J. Practice variation and missed opportunities for reperfusion in ST segment elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359: 373-7.
5. Carruthers KF, Dabbous OH, Flather MD, et al. The Global Registry of Acute Coronary Events (GRACE). Contemporary management of acute coronary syndromes: does the practice match the evidence? Heart 2005; 91: 290-8.
6. Fox KA, Goodman SG, Anderson FA Jr, et al., on behalf of the GRACE investigators. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart 2003; 24: 1414-24.
7. Gandjour A, Kleinschmit F, Lauterbach KW. European comparison of costs and quality in the treatment of acute myocardial infarction (2000-2001). Eur Heart J 2002; 23: 858-68.
8. Zubaid M, Rashed WA, Husain M, et al. A registry of acute myocardial infarction in Kuwait: patient characteristics and practice patterns. Can J Cardiol 2004; 20: 783-7.
9. Rashed W, Zubaid M, David T, et al. Patient characteristics and practice patterns in the treatment of acute myocardial infraction in Kuwait: a pilot study. Med Princ Pract 2002; 11: 196-201.
10. Zubaid M, Rashed W, AlKhaja N, et al. Clinical presentation and outcomes of acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Saudi Med J 2008; 29: 251-5.
11. Cannon CP, Battler A, Brindis RG, et at. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001; 38: 2114-30.
12. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
13. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
14. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
15. Bonnefoy E, Lapostolle F, Leizorovicz A, et al., for the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction Study Group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-9.
16. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-6.
17. Andersen HR, Nielsen TT, Rasmussen K, et al., for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-42.
18. Aversano T, Aversano LT, Passamani E, et al., for the Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002; 287: 1943-51
19. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993; 22: 376-80.
20. Grinfeld L, Berrocal D, Bellardi J, et al. Fibrinolytics versus primary angioplasty in acute myocardial infarction (FAP): a randomized trial in a community hospital in Argentina. J Am Coll Cardiol 1996; 27: A222.
21. Grines CL, Browne KF, Marco J, et al., for the Primary Angioplasty in Myocardial Infarction Study Group. Acomparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-9.
22. Gibbons RJ, Holmes DR, Reeder GS, et al., for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685-91.
23. Sabatine MS, Cannon CP, Gibson CM, et al., for the CLARITYTIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
24. Chen ZM, Pan HC, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1622-32.
25. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2008; 51: 210-47.
26. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001; 345: 494-502.
27. The Scandinavian Simvastatin Survival group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
28. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
29. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl Med 1998; 339: 1349-57.
30. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263-70.
31. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995; 92: 3132-7.
32. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
33. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.
34. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-7.
35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
36. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
37. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. The Lancet 1995; 345: 669-82.
38. Cannon CP, Braunwald E, Mc CabeCH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1562-4.
39. The European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
40. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2-3.